*Immunovant: In Light of Evolving Sjögren's Disease Landscape and Recent Data in the Field, Expect It Is Unlikely That We Will Advance IMVT-1402 Further in SjD Beyond the Ongoing, Fully Enrolled Phase 2 Trial >IMVT

Dow Jones · 2d ago

Please log in to view news